Statins and Liver Toxicity: A Meta‐Analysis

Pharmacotherapy - Tập 24 Số 5 - Trang 584-591 - 2004
Simon de Denus1, Sarah A. Spinler2,1, Kristin Miller1, Andrew M. Peterson1
1Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, Pennsylvania.
2Department of Medicine, Division of Cardiology, University of Pennsylvania, Philadelphia, Pennsylvania

Tóm tắt

Study Objective. To assess the risk of liver function test (LFT) abnormalities with the use of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors (statins) for the treatment of hyperlipidemia.Design. Meta‐analysis of randomized, placebo‐controlled trials of statins used for the treatment of hyperlipidemia or for primary or secondary prevention of cardiovascular disease.Setting. University research center.Patients. A total of 49,275 patients from 13 trials.Intervention. A literature search of published clinical trials was performed in MEDLINE (January 1966–March 2003) and the Cochrane Controlled Trials Registry (first quarter 2003). Studies also were identified from the references of the trials and of published systematic reviews.Measurements and Main Results. For a trial to be included in the meta‐analysis, its duration of follow‐up had to be at least 48 weeks and the trial had to include at least 400 patients, with at least 200 treated with a statin. Trials conducted in transplant recipients were excluded. The proportion of patients having LFT abnormalities was low in both groups (statins 1.14% vs placebo 1.05%, odds ratio [OR] 1.26, 95% confidence interval [CI] 0.99–1.62, p=0.07). Only fluvastatin was associated with a significant increase in the odds of having LFT abnormalities (fluvastatin 1.13% vs placebo 0.29%, OR 3.54, 95% CI 1.1–11.6, p=0.04) compared with placebo, although this finding was based on only two trials.Conclusions. Our results support previous observations that pravastatin, lovastatin, and simvastatin at low‐to‐moderate doses are not associated with a significant risk of LFT abnormalities. Additional data are required to determine whether other statins have a similar safety profile.

Từ khóa


Tài liệu tham khảo

Anonymous., 2002, Integrated management of cardiovascular risk, 1

10.1592/phco.22.11.853.33623

10.1016/0002-9343(86)90158-0

10.1001/jama.279.20.1615

10.1056/NEJM199511163332001

Scandinavian Simvastatin Survival Study Group., 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S), Lancet, 344, 1383

10.1056/NEJM199811053391902

10.1056/NEJM199610033351401

10.1016/S0140-6736(02)09327-3

Anonymous., 2003, Top 200 brand‐name drugs by units in 2002, Drug Top, 6, 60

10.1001/jama.285.19.2486

10.1345/aph.1A413

10.1016/S0735-1097(02)02030-2

Merck and Co. Inc.Mevacor (lovastatin) package insert. Whitehouse Station NJ;2002.

Novartis Pharmaceuticals Canada Inc.Lescol (fluvastatin) package insert. Dorval Quebec;2002.

Pfizer Inc.Lipitor (atorvastatin) package insert. New York NY;2002.

Bristol‐Myers Company.Pravachol (pravastatin) package insert. Princeton NJ;2003.

Merck and Co. Inc.Zocor (simvastatin) package insert. Whitehouse Station NJ;2003.

10.1016/S0002-9149(02)02590-0

10.1016/S0002-9149(02)02355-X

10.1001/archinte.163.6.688

10.1001/archinte.1991.00400010067008

10.1345/aph.10228

10.1161/01.CIR.90.4.1679

LaRosa J.C., 1994, Cholesterol lowering in the elderly: results of the cholesterol reduction in seniors program (CRISP) pilot study, Arch Intern Med, 154, 529, 10.1001/archinte.1994.00420050081008

10.1093/eurheartj/15.suppl_3.255

10.1161/01.CIR.92.7.1758

10.1016/S0002-9149(97)00346-9

10.1001/jama.287.24.3215

10.1016/S0140-6736(02)11600-X

10.1161/01.CIR.103.13.1721

10.1161/01.CIR.102.15.1748

10.1161/01.CIR.91.10.2528

10.1053/euhj.2002.3291

10.1016/0735-1097(95)00301-0

10.1016/S0140-6736(03)12948-0

Shadish W.R., 1994, The handbook of research synthesis, 261

10.1016/S0735-1097(02)01913-7

10.1345/aph.1C116

10.1016/S0002-9343(01)00870-1

10.1056/NEJM200202143460721

10.1161/01.CIR.0000017634.00171.24

10.1016/S0009-9236(03)00121-8

10.1038/sj.tpj.6500144

10.1001/archinte.163.6.657

10.1001/jama.285.13.1711

10.1001/jama.291.9.1071

10.1056/NEJMoa040583

10.1016/S0140-6736(02)07442-1

Thông tin
Thông tin xuất bản

Pharmacotherapy

Tập 24 Số 5

584-591

Thông tin tác giả